MeSH tree: D02.092.471
The new "Clinical Practice Guideline for the Appropriate Use of Methylenedioxymethamphetamine-assisted psychotherapy (MDMA-AP) for Post-Traumatic Stress Disorder (PTSD)" has been approved by the National Health and Medical ...
Feb 12, 2026
0
17
In the national conversation about overdose, fentanyl is often framed as a single, wide-reaching crisis, but new evidence from five major U.S. cities suggests a more fragmented, complex reality. In an article published in ...
Feb 10, 2026
0
28
For people with migraine, summer can be a double-edged sword. You may be able to relax more, sleep in, enjoy the sunshine, and spend time with family and friends.
Jan 29, 2026
0
8
The use of medications for Attention-Deficit Hyperactivity Disorder (ADHD) has increased substantially across Europe over the past decade, with the steepest rises seen among adults—particularly women—according to a large ...
Jan 25, 2026
0
24
Methamphetamine doesn't just spike levels of the pleasure-inducing hormone dopamine in the reward pathways of the brain—it also provokes damaging brain inflammation through similar mechanisms.
Jan 18, 2026
0
26
Once considered a regional problem, methamphetamine-related overdose deaths have risen across every U.S. Census division, with particularly sharp spikes in the Southeast, including Mississippi, a new study reveals.
Jan 12, 2026
0
56
A multiyear community asthma program on the Navajo Nation increased asthma-related care and awareness among families, even as the COVID-19 pandemic dramatically disrupted health care and school systems. The findings come ...
Jan 7, 2026
0
7
When Canada legalized cannabis in October 2018, there were many concerns about its potential impacts. One of them involved cannabis-impaired driving.
Dec 21, 2025
0
65
New research from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King's College London has provided the first direct evidence that schizophrenia is associated with a greater release of serotonin in the ...
Dec 21, 2025
0
64
Annual prescriptions for drugs to treat attention-deficit/hyperactivity disorder (ADHD) increased 157% in Ontario from 2015 to 2023, according to a new study from researchers at ICES, North York General, and The Hospital ...
Dec 11, 2025
0
13
